Skip to content
  • What We Do
    • Financial Statements
    • Disclosures
    • Privacy
    • Terms Of Use
    • Multi-Asset Clearing 
    • Technology
    • Investment Banking & Capital Markets
    • Equity Research
    • Prime Brokerage
    • Wealth Management
    • Investment Management
    • List Item #1
    • List Item #2
    • List Item #3
    • List Item
    • List Item
  • Solution Guide
  • Company
    • Financial Statements
    • Disclosures
    • Privacy
    • Terms Of Use
    • About Us
    • Leadership
    • Career Opportunities
    • Community
    • Affiliates
  • Insights
  • What We Do
    • Financial Statements
    • Disclosures
    • Privacy
    • Terms Of Use
    • Multi-Asset Clearing 
    • Technology
    • Investment Banking & Capital Markets
    • Equity Research
    • Prime Brokerage
    • Wealth Management
    • Investment Management
    • List Item #1
    • List Item #2
    • List Item #3
    • List Item
    • List Item
  • Solution Guide
  • Company
    • Financial Statements
    • Disclosures
    • Privacy
    • Terms Of Use
    • About Us
    • Leadership
    • Career Opportunities
    • Community
    • Affiliates
  • Insights
Contact Us
Login
What We Do
  • Multi-Asset Clearing
  • Technology
  • Equity Research
  • Prime Brokerage
  • Wealth Management
  • Investment Management
Solution Guide
Company
  • About Us
  • A Look Back
  • Ed’s Edicts
  • Leadership
  • Career Opportunities
  • Community
  • Financial Statements
  • Find a Financial Professional
Insights
Search
Contact Us

Day: May 15, 2019

Daniel Ives: Strongly Encourage Investors to Stay the Course on Apple

For more on Daniel Ives’ comments: 5 Top Stocks to Buy on Trade War Weakness

Peter Winter: Potential Risk Brewing To The Multi-Family Lending Business In New York

For more on Peter Winter’s comments: NYC-Exposed Banks Fall as Wedbush Warns of Threat From Democrats

David Nierengarten: Impressively Broad Pipeline Are Sources Of Future Value

For more on David Nierengarten’s comments: Bluebird Bio’s Pricing Plan Worries One Biotech Analyst. Here’s Why.

Daniel Ives: Financial Services They Provide Diversify Revenue Streams

For more on Daniel Ives’ comments: Uber’s IPO flop bodes ill for Grab and Go-Jek

David Nierengarten: We See Risks To The ZYNTEGLO (LentiGlobin) Launch

For more on David Nierengarten’s comments: Traders Get Temporary Lyft But Need an Uber Rally: Taking Stock

Find a Financial Professional

Get the support you need to plan your financial future.
Find Now
  • What We Do
  • Solution Guide
  • Company
  • Insights
  • Contact Us
  • Financial Statements
  • Wedbush & Co.
  • Disclosures
  • Privacy
  • Terms Of Use
  • Member NYSE / FINRA / SIPC
  • Broker Check
  • 225 S. Lake Ave., Penthouse, Pasadena | CA | 91101
  • 213.688.8000